GeneQuantum Healthcare Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This GeneQuantum Healthcare Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
GeneQuantum Healthcare presents a practical BD-screening case because its returned pipeline contains 28 records and the deal search returned 16 transaction records. The lead returned asset is GQ-1005, associated with HER2 and HER2 Positive Breast Cancer, HER2-Low Breast Carcinoma, HER2-Low Gastric Cancer, at Phase 3. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | GQ-1005 | GeneQuantum Healthcare (Suzhou) Co. Ltd. | Phase 3 | Pipeline record: HER2; HER2 Positive Breast Cancer, HER2-Low Breast Carcinoma, HER2-Low Gastric Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum | Phase 3 asset with HER2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | GQ-1010 | GeneQuantum Healthcare (Suzhou) Co. Ltd. | Phase 2 | Pipeline record: Trop-2; Advanced Malignant Solid Neoplasm, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Biohaven获得启德医药与AimedBio联合开发的FGFR3靶点同类首创ADC药物的全球开发和商业化权益 | Phase 2 asset with Trop-2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | GQ-1001 | GeneQuantum Healthcare (Suzhou) Co. Ltd. | Phase 2 | Pipeline record: HER2 x Tubulin; Metastatic human epidermal growth factor 2 positive carcinoma of breast, Advanced Malignant Solid Neoplasm, HER2 positive Biliary Tract Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 启德医药与AimedBio达成一项偶联平台技术授权的多靶点创新ADC药物开发合作协议 | Phase 2 asset with HER2 x Tubulin exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | GQ-1007 | GeneQuantum Healthcare (Suzhou) Co. Ltd. | Phase 1 | Pipeline record: HER2; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum | Phase 1 asset with HER2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | AMB-302 | GeneQuantum Healthcare (Suzhou) Co. Ltd. | IND Approval | Pipeline record: FGFR3; Solid tumor, Bladder Cancer, Glioblastoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Biohaven获得启德医药与AimedBio联合开发的FGFR3靶点同类首创ADC药物的全球开发和商业化权益 | IND Approval asset with FGFR3 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2025-08-19 | Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum | Active | disclosed: false |
| 2025-01-24 | Biohaven获得启德医药与AimedBio联合开发的FGFR3靶点同类首创ADC药物的全球开发和商业化权益 | Active | disclosed: false |
| 2025-01-24 | 启德医药与AimedBio达成一项偶联平台技术授权的多靶点创新ADC药物开发合作协议 | Active | disclosed: false |
The most relevant returned precedent is: Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum (2025-08-19). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- GeoVax Labs, Inc. - Prospectus(U.S. Stocks): GeoVax Labs, Inc. - Prospectus(U.S. Stocks) Liquidity and Capital Resources Net cash provided by financing activities was $2,679,809 and $-0- for the nine-month periods ended September 30, 2015 and 2014, respectively. The increase is related to our February 2015 financing discussed below. The NIH has funded the costs of conducting all of our human clinical trials (Phase 1 and Phase 2a) to date for our preventive HIV vaccines, with GeoVax incurring certain costs associated with manufacturing the clinical vaccine supplies and other study support. We also expect the NIH to fully fund the cost of another Phase 1 trial (HVTN 114) of our preventive HIV vaccine to begin in late 2015, which will investigate the effect of adding a “protein boost” component to our vaccine. While efforts are underway
- GENINUS - Quarterly Report(2024.09): GENINUS - Quarterly Report(2024.09) 가. 매출실적 LiquidSCAN은 암 유전체 진단을 위한 액체생검 플랫폼으로 NGS 기반 액체생검 기술을 이 용한 비침습적 정밀의료 암 유전체 진단을 구현합니다. 당사 고유의 분자바코딩 기술을 통한 극미량의 ctDNA(Circulating Tumor DNA: 혈중 종양 유래 DNA) 검출이 가능한 수준의 민 감도 및 특이도를 확보했습니다. 현재 폐암을 적응증으로 44개 유전자 변이 분석 및 항암치 료방법 결정 관련 연구에 활용되고 있으며, 국내 상급 종합병원 NGS 임상 검사실 및 글로벌 제약사 임상 연구에도 활용하고 있습니다. 또한 신장암, 방광암, 췌장암 유전자를 기반으로 비뇨기 특화된 패널을 개발하고 있습니다. (4) HealthSCAN HealthSCAN의 마케팅 전략은 대형병원 중심의 건강검진 수검자 확대를 첫 번째 전략으로 합니다. 이와 동시에 신규 거래처 확대를 시도하고 있습니다. 기존 주요 거래처인 직장인 정 기 건강검진 대상자 중심의 검사 건수 확대를 통한 매출 상승을 도모하고, 대형병원, 준종합 병원, 개인병원, 대형검진센터 대상으로 신규 거래처 확보를 위한 영업활동을 강화하고 있습 니다. 5. 위험관리 및 파생거래 (1) 재무위험 관리 연결회사는 경영활동과 관련하여 신용위험, 유동성위험 및 시장위험 등 다양한 금융위험에 노출되어 있습니다. 연결회사는 금융위험이 경영에 미칠 수 있는 불리한 효과를 최소화하기 위해 노력하고 있습니다. (2) 신용위험 관리 1) 위험 관리 연결회사는 신용위험을 관리하기 위하여 신용도가 일정 수준
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether GeneQuantum Healthcare is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
GeneQuantum Healthcare merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate GQ-1005, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
